Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II-III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study.
van der Voort A, Louis FM, van Ramshorst MS, Kessels R, Mandjes IA, Kemper I, Agterof MJ, van der Steeg WA, Heijns JB, van Bekkum ML, Siemerink EJ, Kuijer PM, Scholten A, Wesseling J, Vrancken Peeters MTFD, Mann RM, Sonke GS; Dutch Breast Cancer Research Group. van der Voort A, et al. Among authors: van ramshorst ms. Lancet Oncol. 2024 May;25(5):603-613. doi: 10.1016/S1470-2045(24)00104-9. Epub 2024 Apr 5. Lancet Oncol. 2024. PMID: 38588682 Clinical Trial.
BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer.
Liefaard MC, van der Voort A, van Ramshorst MS, Sanders J, Vonk S, Horlings HM, Siesling S, de Munck L, van Leeuwen AE, Kleijn M, Mittempergher L, Kuilman MM, Glas AM, Wesseling J, Lips EH, Sonke GS. Liefaard MC, et al. Among authors: van ramshorst ms. Breast Cancer Res. 2023 Jun 19;25(1):71. doi: 10.1186/s13058-023-01664-x. Breast Cancer Res. 2023. PMID: 37337299 Free PMC article.
Efficacy of neoadjuvant treatment with or without pertuzumab in patients with stage II and III HER2-positive breast cancer: a nationwide cohort analysis of pathologic response and 5-year survival.
van der Voort A, Liefaard MC, van Ramshorst MS, van Werkhoven E, Sanders J, Wesseling J, Scholten A, Vrancken Peeters MJTFD, de Munck L, Siesling S, Sonke GS. van der Voort A, et al. Among authors: van ramshorst ms. Breast. 2022 Oct;65:110-115. doi: 10.1016/j.breast.2022.07.005. Epub 2022 Jul 13. Breast. 2022. PMID: 35921798 Free PMC article.
Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial.
van der Voort A, van Ramshorst MS, van Werkhoven ED, Mandjes IA, Kemper I, Vulink AJ, Oving IM, Honkoop AH, Tick LW, van de Wouw AJ, Mandigers CM, van Warmerdam LJ, Wesseling J, Vrancken Peeters MT, Linn SC, Sonke GS. van der Voort A, et al. Among authors: van ramshorst ms. JAMA Oncol. 2021 Jul 1;7(7):978-984. doi: 10.1001/jamaoncol.2021.1371. JAMA Oncol. 2021. PMID: 34014249 Free PMC article. Clinical Trial.
Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer.
Groen EJ, van der Noordaa MEM, Schaapveld M, Sonke GS, Mann RM, van Ramshorst MS, Lips EH, Vrancken Peeters MTFD, van Duijnhoven FH, Wesseling J. Groen EJ, et al. Among authors: van ramshorst ms. Breast Cancer Res Treat. 2021 Aug;189(1):213-224. doi: 10.1007/s10549-021-06235-2. Epub 2021 May 4. Breast Cancer Res Treat. 2021. PMID: 33945043 Free PMC article.
Adjuvant chemotherapy in small node-negative triple-negative breast cancer.
Steenbruggen TG, van Werkhoven E, van Ramshorst MS, Dezentjé VO, Kok M, Linn SC, Siesling S, Sonke GS. Steenbruggen TG, et al. Among authors: van ramshorst ms. Eur J Cancer. 2020 Aug;135:66-74. doi: 10.1016/j.ejca.2020.04.033. Epub 2020 Jun 14. Eur J Cancer. 2020. PMID: 32554215
Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore.
Steenbruggen TG, van Seijen M, Janssen LM, van Ramshorst MS, van Werkhoven E, Vrancken Peeters MTDF, Wesseling J, Lips EH, Sonke GS. Steenbruggen TG, et al. Among authors: van ramshorst ms. Clin Cancer Res. 2019 Aug 15;25(16):4985-4992. doi: 10.1158/1078-0432.CCR-19-0560. Epub 2019 May 10. Clin Cancer Res. 2019. PMID: 31076546
Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
van Ramshorst MS, van der Voort A, van Werkhoven ED, Mandjes IA, Kemper I, Dezentjé VO, Oving IM, Honkoop AH, Tick LW, van de Wouw AJ, Mandigers CM, van Warmerdam LJ, Wesseling J, Vrancken Peeters MT, Linn SC, Sonke GS; Dutch Breast Cancer Research Group (BOOG). van Ramshorst MS, et al. Lancet Oncol. 2018 Dec;19(12):1630-1640. doi: 10.1016/S1470-2045(18)30570-9. Epub 2018 Nov 6. Lancet Oncol. 2018. PMID: 30413379 Clinical Trial.
Additional value of 18F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer.
van Ramshorst MS, Teixeira SC, Koolen BB, Pengel KE, Gilhuijs KG, Wesseling J, Rodenhuis S, Valdés Olmos RA, Rutgers EJ, Vogel WV, Sonke GS, Vrancken Peeters MT. van Ramshorst MS, et al. Cancer Imaging. 2017 May 25;17(1):15. doi: 10.1186/s40644-017-0117-5. Cancer Imaging. 2017. PMID: 28545563 Free PMC article.
19 results